About Lymphoma > Treatment >  Bone Marrow and Stem Cell Transplants
 
Comparing Auto/Allo Stem Cell Transplants

Last update: 09/23/2005

TOPIC SEARCH: ASCO | Medscape | PubMed 
AutoSCT vs.AlloSCT for relapsed indolent lymphoma - PubMed

Articles | Summary of Advantages and Disadvantages

Articles:

• Allogeneic vs. Autologous Transplantation for Indolent Non Hodgkin's Lymphoma, Bruce Cheson, MD National Cancer Institute John G. Gribben, MD Harvard Medical School  - WebCast PAL/Healthology

• Transplantation: Autologous vs. Allogeneic vs. Mini 
  Hosted by: Sandra J. Horning, MD -  lymphoma.org.healthology.com 

• Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma -  Blood First Edition Paper July 31, 2003 - Summary | Full Text

• Syngeneic* Hematopoietic Stem-Cell Transplantation for Non-Hodgkin's Lymphoma: 
   
  A Comparison With Allogeneic and Autologous Transplantation - Readable abstract
  (Syngeneic. The donor is an identical twin of the patient.)

• Autologous followed by Allogeneic (tandem) - Related PubMed abstracts

Summary of Advantages and Disadvantages

Potential Advantages of Auto Transplants:

• High dose therapies made possible by prior harvesting and subsequent engraftment may:

  • decrease risk of disease recurrence and/or curing aggressive component of the disease. 

  • produce a durable remission.

• Avoid Graft versus Host disease 
  (compared to allogeneic SCT)

Potential Problems with Auto Transplants:

• Engrafted cells can be contaminated with disease (compared to allogeneic SCT)

• Increases risk of MDS/secondary AML 

• High Treatment Related Mortality (TRM)

  • Regimen related toxicity

  • Infection during and following conditioning therapy until engraftment takes.

Potential Advantages of Allo Transplants:

• Tumor free graft 

• Undamaged Stem Cells 

• Avoidance of MDS/secondary AML 

• Graft versus lymphoma effect

Potential Problems with Allo Transplants:

• Lack of suitable donors

• High Treatment Related Mortality
   

  • Regimen related toxicity

  • Infection

  • Graft versus Host Disease (See GVHD for details)
    (not a risk for auto SCT type)

Adapted from: Allogeneic Transplantation in Lymphoma
File Format: Microsoft Powerpoint 97 - View as HTML